Skip to Content

From the Lab: Biotechnology

New publications, experiments and breakthroughs in biotechnology–and what they mean.
February 19, 2008

Test for Cancer Cells in Blood
An inexpensive microfluidic chip could lead to earlier cancer detection and treatment.

When blood flows through the microfluidic device, cancer cells in the blood (shown in yellow) stick to microscopic posts lining the chip (shown in blue).

Source: “Isolation of rare cultivating tumour cells in cancer patients by microchip technology”
Mehmet Toner et al.
Nature 450: 1235-1239

Results: A microfluidic device designed by researchers at Massachusetts General Hospital in Boston can detect very low blood levels of cells from malignant tumors. In initial tests, the low-cost device detected such cells in the blood of all but one of 116 patients with various types of cancer.

Why it matters: A malignant tumor continually sheds cells into the bloodstream, spreading cancer to other tissues. Changes in the number of circulating cancer cells indicate changes in the size of the tumor during treatment. A cheap way to detect and monitor those cancer cells could allow doctors to regularly assess the effectiveness of treatment, as they do by measuring levels of viral RNA in HIV patients. Researchers can also examine cells captured on the microfluidic chip for molecular markers that suggest a more aggressive form of cancer or a type of tumor that will respond to specific drugs.

Methods: The device consists of a business-card-size silicon chip dotted with 80,000 microscopic posts. Each post is coated with a molecule that binds to a specific protein found on most cells originating from solid tumors, such as those found in breast, lung, and prostate cancer. As blood flows through small channels in the chip, tumor cells stick to the posts.

Next steps: Larger clinical trials involving patients with lung and prostate cancer will help determine how best to use the chip.

New Stem Cells Cure Disorder in Mice
The findings demonstrate how these cells could be used in human therapies

Source: “Treatment of sickle cell anemia mouse model with IPS cells generated from autologous skin”
Tim M. Townes, Rudolf Jaenisch, et al.
Science 318: 1920-1923, published online December 6, 2007

Results: Scientists have cured a blood disease in mice using cells from the animals’ tails. A new technique that does not require the use of embryos enabled the researchers to reprogram the cells to behave like embryonic stem cells.

Why it matters: The findings are the first to demonstrate the potential of such cells, known as induced pluripotent cells, in treating disease. The cells have been the source of great excitement among both researchers and the public because they hold therapeutic promise and because they sidestep the major ethical concern associated with embryonic stem cells: the destruction of embryos.

Methods: Rudolf Jaenisch and his colleagues at the Whitehead Institute for Biomedical Research in Cambridge, MA, reprogrammed the mouse tail cells to express four genes that are normally active only during embryonic development. After correcting the genetic defect responsible for sickle-cell anemia, they treated the cells with growth factors to trigger the development of blood-­forming stem cells. Mere days after the researchers injected the stem cells into the animals’ bone marrow, symptoms of the disease had reversed.

Next steps: Scientists are concerned that the mechanism used to reprogram the cells to make them pluripotent could increase the risk of cancer. To make the cells safe for human use, the researchers are developing alternative methods.

Keep Reading

Most Popular

This startup wants to copy you into an embryo for organ harvesting

With plans to create realistic synthetic embryos, grown in jars, Renewal Bio is on a journey to the horizon of science and ethics.

VR is as good as psychedelics at helping people reach transcendence

On key metrics, a VR experience elicited a response indistinguishable from subjects who took medium doses of LSD or magic mushrooms.

This nanoparticle could be the key to a universal covid vaccine

Ending the covid pandemic might well require a vaccine that protects against any new strains. Researchers may have found a strategy that will work.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.